News tagged with tyrosine kinase inhibitors

Related topics:

Economic analysis: Erlotinib marginally cost-effective

Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally ...

Feb 16, 2010
not rated yet 0